Alcobra Ltd. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Alcobra Ltd. | ADHD - |
$10.00-$12.00 |
$8.00 |
$8.25 | 3.125 million | 5/22/2013 |
| Aegis Capital Corp |
Co-Manager(s): Sunrise Securities Corp.,Feltl & Company, Inc |
| Health Care |
Filing(s):
Filed 2013-01-14
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Alcobra Ltd. , and our comprehensive analysis, click "Buy Market Research".
Alcobra Ltd. Quote & Chart - Click for current quote -
ADHD
About Alcobra Ltd. (adapted from Alcobra Ltd. prospectus):
They are an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder, or ADHD.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ADHD" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved
